home / stock / vigl / vigl news

VIGL News and Press, Vigil Neuroscience Inc. From 11/07/23

Stock Information
Company Name: Vigil Neuroscience Inc.
Stock Symbol: VIGL
Market: NASDAQ
Website: vigilneuro.com
Menu
VIGL VIGL Quote VIGL Short VIGL News VIGL Articles VIGL Message Board
Get VIGL Alerts

News, Short Squeeze, Breakout and More Instantly...
VIGL - Vigil Neuroscience GAAP EPS of -$0.53 beats by $0.03

2023-11-07 08:41:43 ET More on Vigil Neuroscience Vigil Neuroscience: Interesting Early Data, Wait For Phase 2 Vigil Neuro rises as dosing starts in Phase 1 trial for Alzheimer’s drug Vigil Neuroscience study for Alzheimer's drug to proceed with FDA restrictio...
VIGL - Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update

– Interim data from 20 mg/kg cohort in IGNITE Phase 2 clinical trial of VGL101 in ALSP on track for this quarter – – First participant dosed in Phase 1 study of VG-3927, the first and only small molecule TREM2 agonist in clinical development for potential treatment of A...

VIGL - Vigil Neuro rises as dosing starts in Phase 1 trial for Alzheimer's drug

2023-10-17 13:07:47 ET More on Vigil Neuroscience Vigil Neuroscience: Interesting Early Data, Wait For Phase 2 Vigil Neuroscience study for Alzheimer's drug to proceed with FDA restrictions Seeking Alpha’s Quant Rating on Vigil Neuroscience Historical ...

VIGL - Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer's Disease

WATERTOWN, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that the Company has dosed its first particip...
VIGL - ,EVA, GRTS and SLGL are among mid-day movers

2023-10-06 13:29:08 ET Gainers: Falcon's Beyond Global  (FBYD) +145% . American Oncology Network  ( AONC ) +53% . Akso Health Group  ( AHG ) +23% . Vigil Neuroscience  ( VIGL ) +20% . NuScale Power Corporation ( SMR )...

VIGL - Vigil Neuroscience to Present at Jefferies Inaugural Biotech CNS/Neuro Summit

WATERTOWN, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that Ivana Magovčević-Liebisch,...

VIGL - Vigil Neuroscience Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for VGL101 for the Treatment of ALSP

WATERTOWN, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that the Committee for Orphan Medicinal Prod...
VIGL - Vigil Neuroscience: Interesting Early Data, Wait For Phase 2

2023-09-18 14:38:55 ET Summary Vigil Neuroscience is developing medicines for neurodegenerative diseases by restoring microglial function. Their lead candidate, VGL101, is a monoclonal antibody agonist of TREM2, a microglial receptor protein involved in regulating microglial activ...

VIGL - AVTX, UP and HOTH among mid-day movers

2023-09-13 14:16:14 ET Gainers: Avalo Therapeutics ( AVTX ) +56% . ZyVersa Therapeutics ( ZVSA ) +41% . Rocket Pharmaceutical ( RCKT ) +35% . Vigil Neuroscience ( VIGL ) +31% . Aspira Women's Health ( AWH ) +27% . Novo Integr...

VIGL - Vigil Neuroscience Presents VGL101 Complete Phase 1 Data and Phase 2 IGNITE Trial Design at the 2023 American Neurological Association Annual Meeting

- Complete Phase 1 data analysis demonstrated that VGL101 continued to have a favorable safety and tolerability profile and proof-of-target engagement in SAD/MAD cohorts up to 60 mg/kg - - On track to report 6-month interim data from IGNITE trial in Q4 2023 from first 6 patients who hav...
Previous 10 Next 10